Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proximicin A is a novel aminofuran natural product and research compound isolated from marine strains of the actinomycete *Verrucosispora*. It is a small molecule heterocyclic peptide characterized by the presence of 4-amino-furan-2-carboxylic acid, making it structurally analogous to netropsin and distamycin. Proximicin A exhibits potent cytostatic and antitumor activity against various human cancer cell lines, including gastric adenocarcinoma, hepatocellular carcinoma, breast carcinoma, and glioblastoma. Its mechanism of action involves selective binding to AT-rich DNA sequences in the minor groove, which induces cell cycle arrest at the G1/S phase transition and triggers apoptosis. Additionally, it has been shown to interact with receptors like HER2. Currently, it remains an investigational compound studied primarily in academic settings for its potential as a broad-spectrum anticancer agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proximicin A.